Expression of VEGF and GFAP in a rat model of traumatic brain injury treated with Honokiol: a biochemical and immunohistochemical study

Authors: Abdurrahman Çetin, Engin Deveci

DOI: 10.5603/FM.a2019.0029
Article type: ORIGINAL ARTICLES
Submitted: 2018-12-06
Accepted: 2019-02-07
Published online: 2019-03-05

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Folia Morphologica" are listed in PubMed.
Expression of VEGF and GFAP in a rat model of traumatic brain injury treated with Honokiol: a biochemical and immunohistochemical study

Abdurrahman Çetin1, Engin Deveci2

1Department of Neurosurgery, University of Health Sciences, Gazi Yaşargil Education and Research Hospital, Diyarbakır, Turkey

2Dicle University, Faculty of Medicine, Department of Histology and Embryology, Diyarbakır, Turkey

Address for correspondence: Engin Deveci, Professor, PhD, Dicle University, Faculty of Medicine, Department of Histology and Embryology, 21280, Diyarbakır, Turkey, tel: +90 412 2488001 Ext. 4443 (Faculty room), fax: +90 412 2488440, e-mail: devecie32@hotmail

ABSTRACT

Traumatic brain injury leads to neuronal damage and neurological dysfunction. The aim of our study was to investigate the antioxidative effect of Honokiol on traumatic brain injury in rats with biochemical, histopathological and immunohistochemical methods. Sprague–Dawley rats were subjected to traumatic brain injury with a weight-drop device using 300g/1m weight/height impact. Forty five rats were divided into three groups as control group, traumatic brain injury (TBI) group and TBI + Honokiol group (5 mg/kg/day, i.p.). Honokiol (5 mg/kg) dissolved in dimethyl sulfoxide (DMSO) was intraperitoneally administered to rats for 7 days after the trauma. At the end of experiment, blood samples were taken from the animals and analyzed with various biochemical markers. Histopathological examination of the trauma group revealed some degenerated pyramidal cells, dilatation and congestion in blood vessels, hyperplasia in endothelial cells, inflammatory cell infiltration around the vein and disruptions in glial extensions. In TBI + Honokiol group, pyramidal neurons showed a decrease in degeneration, slight dilatation in blood vessels, improvement of endothelial cells towards the lumen, and reduction of inflammatory cells in the vessel. In TBI + Honokiol group, vascular endothelial growth factor (VEGF) expression was positive in the endothelial and few inflammatory cells of the mildly dilated blood vessels. In the blood brain
barrier deteriorated after trauma, it was observed that the glial foot processes were positive expression and extended to the endothelial cells in the TBI + Honokiol group.

Glial fibrillary acidic protein (GFAP) expression showed a positive reaction in these processes. Considering the important role of antioxidants and inflammatory responses in cerebral damage induced by traumatic head injury, honokiol is thought to be important in decreasing lipid peroxidation, protecting the membrane structure of blood brain barrier, degeneration of neurons and glial cells.

**Key words: traumatic brain injury, Honokiol, vascular endothelial growth factor (VEGF), glial fibrillary acidic protein, rat**

**INTRODUCTION**

Traumatic brain injury is a health problem known as the cause of mortality and disability in young people. Primary and secondary injury cascades that cause delayed neuronal dysfunction, synapse loss and cell death are associated with TBI (1,2). Secondary damage develops within the minutes to days following the primary insult, release of the inflammatory mediators, formation of the free radicals, excessive release of the neurotransmitters (glutamate and aspartate), influx of calcium and sodium ions into neurons, and dysfunction of mitochondria (3). At a cellular level, the biphasic nature of secondary injury is mediated by numerous disturbed pathways which include: excitotoxicity caused by an excess of the neurotransmitter glutamate; free radical generation by dysfunctional mitochondria, causing damage to proteins and phospholipid membranes of neurons and glia; the neuroinflammatory response which takes place due to both brain parenchyma and systemic immunoactivation (3,4). Glutamate is an excitatory amino acid which is known to play a role in the pathological events, increasing brain-blood barrier permeability and the occurrence of oxidant damage. Previous studies have shown that glutamate antagonists may be beneficial in several conditions, such as ischemia, sepsis and trauma (2,3). The neuroinflammation is closely related to the overproduction of the reactive oxygen species which cause many neuropathologies. Free radicals damage various cellular components, including proteins, lipids and deoxyribonucleic acid. Antioxidants and anti-inflammatory drugs were widely studied in neurotrauma models (4). After trauma, depending on the degree of brain damage, neuroinflammation, cerebral edema and blood-brain barrier fragmentation
occur. Vascular endothelial growth factor is a trophic factor that is expressed in the central nervous system after injury (5) and induces angiogenesis (6). Inhibition of VEGF expression after trauma may exacerbate neuronal and glial injury (7). However, increased endogenous VEGF interacts with ischemic vessels with its receptors and contributes to the deterioration of the blood-brain barrier and subsequent leakage (8).

Glial fibrillary acidic protein is an intermediate filament protein found in the skeleton of astroglia. Data from studies have shown that increased local tissue GFAP immunoreactivity is a sensitive indicator of neuronal damage and its increase is considered to be a determinant of reactive astrocytosis. GFAP level in blood fluid increases when cerebral tissue or spinal cord cells are damaged due to trauma or disease (9-11). This marker is in fact an indicator of the reaction of astrocytes in the form reactive gliosis.

Honokiol is a natural biphenolic compound that is isolated from magnolia bark and has been used in the traditional Chinese and Japanese medicine as an antibacterial, antiemetic, antidepressant, antithrombotic, and anxiolytic agent. Studies have shown therapeutic effects including antioxidative and anti-inflammatory activities for honokiol (12-14).

Traumatic brain injury animal models are important in developing diagnostic and therapeutic strategies for understanding the pathophysiology of brain shocks (15). In this study, antioxidative effects of honokiol on neuronal structures and changes in blood brain barrier were investigated in traumatic brain injury. In this study, we aimed to investigate antioxidative effects of honokiol on neuronal structures in a traumatic brain injury model in rats with biochemical, histopathological and immunohistochemical methods.

MATERIAL AND METHODS

Animals

Every single surgical methodology and the consequent care and healing of the animals utilized as a part of this investigation were in strict understanding with the National Institutes of Health (NIH Publications No. 8023, revised 1978) rules for animal care. All techniques performed in this examination were approved by the Ethics Committee for Animal Experimentation of the Faculty of Medicine at Dicle University, Turkey. Male Sprague-Dawley rats (250–280 g) were housed in an air-conditioned room with 12-h light and dark cycles, where the temperature (23±2°C) and relative humidity (65–70%) were kept constant. All rats at the end of experiment were healthy and no difference in food/water consumption and body weight gain between experimental and control rats were observed.
**Traumatic brain injury model**

**Sedation procedure:** The animals were anesthetized by an intraperitoneal injection of 5 mg/kg xylazine HCl (Rompun, Bayer Health Care AG, Germany) and 40 mg/kg ketamine HCl (Ketalar, Pfizer Inc., USA), and were allowed to breathe spontaneously. A rectal probe was inserted, and the animals were positioned on a heating pad that maintained the body temperature at 37 °C.

Three groups (15 rats per group) were arranged as below:

1. **Control group:** Isotonic saline solution (an equal volume of Honokiol) was administered i.p. for 7 days.

2. **TBI group:** The widely used diffuse brain injury model described by Marmarou et al. was used (4). Briefly, a trauma device which works by dropping a constant weight from a specific height through a tube was used. A weight of 300 g was dropped from a 1 m height, which can induce mild trauma, as shown by Ucar et al. (16).

3. **TBI+ Honokiol group:** Honokiol (5 mg/kg; Sigma-Aldrich Inc., St. Louis, MO, USA) dissolved in DMSO was intraperitoneally administered for 7 days after the trauma. After seven days, all animals were sacrificed by an intraperitoneal injection of 5 mg/kg xylazine HCl (Rompun, Bayer HealthCare AG, Germany) and 40 mg/kg ketamine HCl (Ketalar, Pfizer Inc, USA). After traumatic brain injury, blood samples were taken from the animals and analyzed with various biochemical markers. Then, parietal lobe of the brain cortex were rapidly removed. For the histological examination, brain tissues were fixed in 10% formaldehyde solution, post-fixed in 70% alcohol, and embedded in paraffin wax. The sections were stained with Hematoxylin-Eosin.

**Malondialdehyde (MDA) and Glutathione peroxidase (GSH-Px) assays**

Tissue samples were homogenized with ice-cold 150 mM KCl for the determination of malondialdehyde and glutathione levels. The MDA levels were assayed for products of lipid peroxidation, and the results are expressed as nmol MDA/g tissue (17). Glutathione was determined by the spectrophotometric method, which was based on the use of Ellman’s reagent, and the results are expressed as μmol glutathione/g tissue (18).

**Myeloperoxidase (MPO) assay**

Myeloperoxidase activity in tissues was measured by a procedure similar to that described by Hillegas et al. (19). Myeloperoxidase activity is expressed as U/g tissue.
**Evans blue assay for blood-brain barrier permeability**

To evaluate the blood-brain barrier integrity, Evans blue (EB) dye was used as a marker of albumin extravasation (20). EB was expressed as μg/mg of brain tissue against a standard curve.

**Immunohistochemical technique**

Formaldehyde-fixed tissue was embedded in paraffin wax for further immunohistochemical examination. Sections were deparaffinized in xylene. Antigen retrieval process was performed twice in citrate buffer solution (pH:6.0), first for 7 minutes, and second for 5 minutes, boiled in a microwave oven at 700 W. They were allowed to cool to room temperature for 30 minutes and washed twice in distilled water for 5 minutes. Endogenous peroxidase activity was blocked in 0.1% hydrogen peroxide for 20 minutes. Ultra V block (Cat. No:85-9043, Invitrogen, Carlsbad, CA, USA) was applied for 10 minutes prior to the overnight application of primary antibodies Vascular Endothelial Growth Factor (VEGF) antibody (Cat. No: RB-222-P0) (1:100 dilution), Glial fibrillary acidic protein (GFAP) antibody (1:100 dilution) (Cat. No: PA3-067, Invitrogen, Carlsbad, CA, USA).

Secondary antibody (Cat.No: 85-9043, Invitrogen, Carlsbad, CA, USA) was applied for 20 minutes. Slides were then exposed to streptavidin–peroxidase for 20 minutes. Chromogen diaminobenzidine (DAB) (Invitrogen, Cat. No:34002 Carlsbad, CA, USA) was used. Control slides were prepared as mentioned above, but omitting the primary antibodies. After counterstaining with hematoxylin, and washing in tap water for 8 minutes and in distilled water for 10 minutes, the slides were mounted with entellan.

**Statistical analysis**

Statistical analysis of biochemical findings was carried out using GraphPad Prism 4.0 software (GraphPad Software, 2003, San Diego, CA, USA). All data are presented as mean ± standard deviation (SD). Groups of data were compared with an analysis of variance (ANOVA) followed by Tukey’s multiple comparison tests. Values of p<0.001 and p<0.01 were considered as statistically significant (Figure 1). For the statistical analysis of VEGF and GFAP expression, Kruskall-Wallis and Mann-Whitney U non-parametric statistical tests were used in the intergroup comparisons depending on the variables and the results were given as the mean ± standard deviation and mean rank. And, the results were considered statistically significant for P=0 with Kruskal-Wallis test and P < 0.05 with Mann-Whitney U test (Table 1).
RESULTS

Biochemical findings

The following biochemical parameters were compared between groups (Figure 1).

Tissue Malondialdehyde (MDA) levels

MDA values in the trauma (TBI) group were significantly higher than those of the control group (p<0.001), while the TBI+ Honokiol group had significantly lower levels than those of the trauma (TBI) group (p<0.001).

Tissue glutathione peroxidase (GSH-Px) levels

GSH-Px levels of the control group were significantly higher than those of the trauma group (p<0.01), while those of the TBI+ Honokiol group were also significantly higher than those of the trauma group (p<0.01).

Tissue myeloperoxidase (MPO) activity

MPO levels of the control group were significantly lower than those of the trauma group (p<0.01), while those of the TBI+ Honokiol group were also significantly lower than those of the trauma group (p<0.01).

Evans Blue (EB) Assay for Blood Brain Barrier Permeability

Blood-BRAIN Barrier permeability values of the control group were significantly lower than those of the trauma group (p<0.001), while those of the TBI+ Honokiol group were also significantly lower than those of the trauma group (p<0.001).
Figure 1. Biochemical results relevant to the study groups.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Groups</th>
<th>n</th>
<th>Mean±SD</th>
<th>Mean Rank</th>
<th>Kruskal-Wallis Test value</th>
<th>Mann-Whitney U comparisons for groups (p&lt;0.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VEGF</strong></td>
<td>(1) Control</td>
<td>15</td>
<td>1.81±0.65</td>
<td>17.08</td>
<td>19.397</td>
<td>*P=0 <strong>(2)</strong></td>
</tr>
<tr>
<td></td>
<td>(2) TBI</td>
<td>15</td>
<td>3.12±0.71</td>
<td>30.12</td>
<td>**P &lt; 0.05 **(1) <strong>(3)</strong></td>
<td><strong>(2)</strong></td>
</tr>
<tr>
<td></td>
<td>(3) TBI+Honokiol</td>
<td>15</td>
<td>2.00±0.73</td>
<td>44.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GFAP</strong></td>
<td>(1) Control</td>
<td>15</td>
<td>3.31±0.60</td>
<td>10.50</td>
<td>34.034</td>
<td>*P=0 <strong>(2)</strong></td>
</tr>
<tr>
<td></td>
<td>(2) TBI</td>
<td>15</td>
<td>1.37±0.61</td>
<td>33.65</td>
<td>**P &lt; 0.05 **(1) <strong>(3)</strong></td>
<td><strong>(2)</strong></td>
</tr>
<tr>
<td></td>
<td>(3) TBI+Honokiol</td>
<td>15</td>
<td>3.06±0.044</td>
<td>47.35</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Histopathological scoring of VEGF and GFAP expressions. Data are expressed as the mean ± standard deviation and mean rank (*P=0 with Kruskal-Wallis test , **P < 0.05 with Mann-Whitney U test, * and ** statistically significant result). The quantification of all parameters: 0: no change, 1: too week, 2: week, 3: middle, 4: strong. (Scoring was determined by examining histological parameters in 15 different regions within the microscope field).

Histopathologic findings
When brain cortex of the control group was examined, the pyramidal neurons were polyhedral and had chromatin-rich nuclei. Glial cells were observed with small round nuclei and distributed solitary.

The lumen of the capillary vessels in the cortex was regular and the endothelial cells were flat (Figure 2a). Histopathological examination of the TBI group revealed some degenerated pyramidal cells, picnotic nuclei, dilated and congested blood vessels, hyperplasia in endothelial cells, inflammatory cell infiltration around the vein and disruptions in glial extensions (Figure 2b). In the histopathological examination of the TBI + Honokiol group, we observed a decrease in degenerated pyramidal neurons, polygonal and dense-chromatin nuclei, slight dilated blood vessels and flattened endothelial cells towards the lumen and decrease in inflammatory cells around the vessel (Figure 2c).

**Immunohistochemical findings**

VEGF expression in the capillary endothelial and some glial cells in the cortex showed a positive reaction in the control group sections (Figure 3a). In the TBI group, glial cells around some degenerated neurons, dilated capillary endothelial cells and vascular inflammatory cells showed increased VEGF expression (Figure 3b). In the TBI + Honokiol group, VEGF expression was positive in the endothelial and few inflammatory cells of the mildly dilated blood vessels (Figure 3c). When GFAP expression was examined in the control group, it was observed that the glial foot processes around the capillary vein covered the basement membrane like a meshwork and were firmly bound to the endothelial cells, and the expression of GFAP protein was significant (Figure 3d). In the TBI group, loss of glial extensions was observed with deterioration of the glial food processes around the dilated capillary vessels. GFAP positive expression was observed in the short thick extensions away from the vessels (Figure 3e). A significant increase in GFAP expression was observed in the glial food processes that covered the lumen of regular capillaries in the TBI + Honokiol group (Figure 3f).
Figure 2a. Hematoxylin and eosin staining, original magnification x40 (Control group). Normal appearance of regular cells and vascular structures in brain cortex.

Figure 2b. Hematoxylin and eosin staining, original magnification x40 (TBI group). Dilation in blood vessels and hemorrhage (yellow arrow), degenerative changes in some neurons, hyperplasia in endothelial cells (red arrow), inflammatory cell infiltration around blood vessels (green arrow) and disruptions in glial extensions.
Figure 2c. Hematoxylin and eosin staining, original magnification x40 (TBI+Honokiol group). Reduction in vascular dilatation (yellow arrow), flat endothelial cells towards the lumen, and decrease in inflammatory cells around the blood vessel (green arrow), regular structure of the nucleus and cytoplasm in neurons and glial cells.

Figure 3a. VEGF immunostaining, original magnification x40 (Control group). VEGF expression in the capillary endothelial (yellow arrow), and some glial cells in the cortex.

Figure 3a*. Negative control, Hematoxyline staining, original magnification x40.
Figure 3b. VEGF immunostaining, original magnification x40 (TBI group). An increase in VEGF expression glial cells around some degenerated neurons and dilated capillary endothelial and vascular inflammatory cells (yellow arrow).

Figure 3b*. Negative control, Hematoxylene staining, original magnification x40.

Figure 3c. VEGF immunostaining, original magnification x40 (TBI+Honokiol group). Positive VEGF expression in the endothelial and few inflammatory cells of the mildly dilated blood vessels (yellow arrow).

Figure 3c*. Negative control, Hematoxylene staining, original magnification x40.
Figure 3d. GFAP immunostaining, original magnification x40 (Control group). Positive GFAP expression in glial food processes around the capillary vessel (yellow arrow).

Figure 3d*. Negative control, Hematoxyline staining, original magnification x40.

Figure 3e. GFAP immunostaining, original magnification x40 (TBI group). Loss and degeneration in glial food processes around the dilated capillary vessels, positive GFAP expression (yellow arrows).

Figure 3e*. Negative control, Hematoxyline staining, original magnification x40.
DISCUSSION

Shortly after TBI, lack of blood flow causes necrotic neuronal death; however, greater loss of apoptotic neurons may then occur after secondary injury of hypoxia/ischemia and oxidative stress and inflammation (21-23).

Previous studies have shown that a variety of pathological factors, such as oxidative stress, the inflammatory response and apoptosis, are involved in secondary brain injury after traumatic brain injury. Furthermore, early interventions to reduce the level of oxidative stress and the extent of the inflammatory response can significantly reduce the extent of traumatic brain injury (24). Baloğlu et al. (25) observed a significant increase in MDA levels in spinal cord injury and a significant decrease in level of GSH and MPO. They have observed degenerative changes in some multipolar and bipolar nerve cells and necrotic changes in the nucleus of glial cells.

TBI initiates a neuroinflammatory cascade characterized by microglial activation and increased production of proinflammatory cytokines (26). Traumatic brain injury often promotes disruption of blood-brain barrier integrity and the neurovascular unit, which can result in vascular leakage, edema, hemorrhage, and hypoxia. Other pathologic mechanisms include cell death within the meninges and brain parenchyma, stretching and tearing of axonal fibers, and disruptions at the junctions between white and gray matter, stemming from rotational forces that cause shearing injuries (27). In this study, histopathological examination
of the TBI group revealed some degenerated pyramidal cells, picnotic nuclei, dilated and congested blood vessels, hyperplasia in endothelial cells, inflammatory cell infiltration around the vein and disruptions in glial extensions (Figure 2b). In the TBI + Honokiol group, pyramidal neurons were less degenerated, also there were slight dilatation of blood vessels, improvement of endothelial cells towards the lumen, and reduction of inflammatory cells in the vessel (Figure 2c). Feng et al. (28) reported that traumatic brain injury can result in synapse loss or damage and may contribute to observed behavioral, cognitive, and neurological disorders.

Vascular endothelial growth factor is effective on vascular and neural development. It was thought that brain edema was dominant because of the increase in VEGF expression and blood-brain barrier destruction in the post-traumatic contusion stage (29,30). Lenzlinger et al. (7) found that inhibition of VEGF significantly reduced regional cerebral edema in TBI rats. Krum and Khaibullina (31) showed that inhibition of vascular endothelial growth factor signals, including VEGF-R1 receptors, decreased the numbers of reactive astrocytes and prevented glial scar formation in traumatic brain injury models. In our TBI group, an increase in VEGF expression levels, vascular permeability, and rapid interaction of VEGF receptors in endothelial cells led to the destruction of vascular wall in the blood brain barrier and the formation of edema. The neuroprotective function of VEGF is thought to be due to a combination of direct neuroprotective effects and stimulation of angiogenesis. GFAP, a brain-specific protein that acts as the major integral component of the cell skeleton of astrocytes, GFAP after brain injury discharges the brain cells into the interstitial fluid in the environment and causes deterioration in the blood-brain barrier (32). An increase in GFAP expression is a cardinal feature of many pathological conditions of the central nervous system and astrocytes. Increasing numbers of GFAP positive expression astroglia cells following TBI have been described in several experimental studies in animals. GFAP was positively expressed in the normal brain tissue, processes in astrocytes around blood brain barrier rupture was defined as significant GFAP expression (9,11). Özevren et al. (33) showed that glial food processes around the blood vessels were decreased and GFAP expression was positive after trauma.

Honokiol with its antioxidant effects was shown to provide protection against cerebral I/R injuries and dermatological disorders (34). It has been reported that Honokiol can provide potential support to clinical trials in ischemia treatment by passing through the blood brain barrier in low-dose long-term treatments (35). Honokiol has been reported to protect the rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and production of reactive oxygen species (14). In a similar way to our study, they investigated
the effects of Honokiol, a cell cycle inhibitor, on neuronal damage reduction and functional recovery after TBI in rats. They demonstrated that Honokiol, intravenously administered, has a strong neuroprotective effect against sensorimotor and cognitive deficits after TBI, which is highly associated with the survival of increased neurons. It has been suggested that the neurocompatibility mediated by Honokiol after TBI may affect the molecular mechanism due to suppression of over-activated cell cycle (36). Talerek et al. (37) have made a comprehensive assessment of the potential molecular mechanisms of action that are considered as a promising agent in the treatment and management of neurodegenerative diseases concerning the neuroprotective effects of honokiol (37). In the experimental studies, it was stated that honokiol plays an active agent role in the central nervous system. Antioxidant activity, inhibition of excitotoxicity; and cell signaling in neuroinflammation has been shown as evidences on its neuroprotective activity (35,38-42). In studies of experimental and human cell culture, it has been reported that honokiol can reduce oxidative stress parameters in several catabolic tissues such as liver (43), endothelial cells (44), muscle tissue (45), heart or kidney (46). However, there is little information in studies demonstrating the oxidative inhibition of honokiol in the central nervous system. Chuang et al. (47) studied the effect of honokiol on oxidative stress and inflammation in neural and microglial cells. They investigated the oxidative and inflammatory responses of these isomers in microglial cells activated by interferon-γ and lipopolysaccharide in suppressing oxidative stress in neuronal stimulated neurons by ionotropic glutamate receptor agonist N-methyl-D-aspartate. And, they also investigated the mechanism and signaling pathways involved in cytokine-induced production of reactive oxygen species in microglial cells. Their results of microglial cells also demonstrated the important role of interferon-γ in stimulating signaling pathways involving activation of extracellular signal-regulated protein kinases 1 and 2, reactive oxygen species and nitric oxide. Studies have shown that honokiol inhibits reactive oxygen species in neutrophils (48) and suppresses the lipopolysaccharide-induced tumor necrosis factor alpha and nitric oxide expression in macrophages (49). In addition, some authors suggest that honokiol can inhibit nuclear factor kappa light chain enhancer of activated B cells activation in mouse B cells (50), macrophages (51) and lipopolysaccharide-induced microglia cells (34). It is also believed that honokiol can selectively modulate the the phosphoinositide 3-kinase / Akt pathway (49,52,53).

CONCLUSIONS
The neuroprotective effect of honokiol was found to be parallel to the reduction of lipid peroxidation and inhibition of inflammatory cell in cerebral tissue. After trauma, the structure of glial food processes deteriorates along with the increase of inflammation towards endothelial cells. Due to the effect of Honokiol, the improvement of vascular wall due to decreased inflammation in this region and the regular distribution of glial food processes define the antioxidative development. Considering the important role of antioxidants and inflammatory responses in cerebral damage induced by traumatic head injury, Honokiol is thought to be important in decreasing lipid peroxidation and protecting the membrane structure of blood brain barrier, degeneration of neurons and glial cells.

REFERENCES


